HIF1A and neoplasm: HIF-1α serum levels in 80 patients harbouring NSCLC and undergoing chemoradiotherapy in a curative intent were assessed [137]: soluble HIF-1α levels were decreased during and after treatment compared to the initial point, suggesting serum HIF-1α concentrations as a potential marker to monitor tumour response during chemoradiation.